Intensive Insulin Therapeutics in Type 2 Diabetes Management

Type 2 diabetes is characterised by progressive insulin resistance and declining pancreatic β-cell function. When lifestyle measures and oral agents fail to maintain glycaemic targets, intensive insulin regimens become essential. By delivering basal and bolus insulin through multiple daily injections or continuous subcutaneous infusion, these strategies more closely mimic physiological secretion, reduce glycaemic variability and alleviate glucotoxic stress on β cells. Early short-term intensive therapy can induce a “β-cell rest” effect, slowing disease progression and enhancing endogenous insulin production. Contemporary protocols integrate personalised dosing algorithms, real-time glucose monitoring and adjunctive incretin co-therapies to optimise efficacy and minimise hypoglycaemia. Globally, such approaches aim to improve long-term microvascular and macrovascular outcomes, enhance quality of life and address the escalating burden of inadequately controlled type 2 diabetes.

Research from Nature Portfolio

Recent studies have delineated predictors of sustained β-cell stabilisation following an induction–maintenance paradigm. Adults with early disease received a 3-week basal–bolus induction followed by metformin maintenance, with or without intermittent insulin courses over 2 years. Sustained improvements in β-cell function were linked to the degree of initial secretory recovery and preserved hepatic insulin sensitivity during maintenance, highlighting targets for optimising regimen design.

A real-world comparison of early insulinisation versus oral antidiabetic therapy in newly diagnosed patients showed non-inferior long-term HbA1c control over 36 months. Although oral regimens trended towards marginally better glycaemic outcomes in some subgroups, findings support flexible initial treatment choices based on patient preference and resource settings.

An open-label trial assessing basal insulin with or without a short-acting GLP-1 receptor agonist in early type 2 diabetes found that exenatide addition yielded lower on-treatment HbA1c but did not enhance β-cell function or remission rates after washout. This underscores the challenge of achieving durable β-cell recovery with adjunctive incretin therapy.

Intensive Insulin Therapeutics in Type 2 Diabetes Management publication trend

The graph below shows the total number of articles in intensive insulin therapeutics in type 2 diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Intensive insulin therapy: Regimens using multiple daily injections or pumps to mimic physiological insulin profile.

Beta-cell function: The capacity of pancreatic β cells to secrete insulin in response to glucose.

Continuous subcutaneous insulin infusion (CSII): Delivery of insulin via a programmable pump for basal and bolus dosing.

Multiple daily injections (MDI): Administration of basal and prandial insulin through separate daily injections.

Glycaemic variability: Fluctuations in blood glucose levels over time, linked to complication risk.

Glycated haemoglobin (HbA1c): A measure of average blood glucose over 2–3 months, expressed as a percentage.

References

1. Real-world effectiveness of early insulin therapy on the incidence of cardiovascular events in newly diagnosed type 2 diabetes. Signal Transduction and Targeted Therapy (2024).
2. Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes. Nature Communications (2023).
3. Oral antidiabetic therapy versus early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: a retrospective matched cohort study. Scientific Reports (2024).
4. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovascular Diabetology (2021).
5. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial. Nature Communications (2022).
6. Casual C peptide index: Predicting the subsequent need for insulin therapy in outpatients with type 2 diabetes under primary care. Journal of Diabetes (2022).